

## CORRIGENDUM

*PIK3CA* mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

S. Loibl, I. Majewski, V. Guarneri, V. Nekljudova, E. Holmes, E. Bria, C. Denkert, C. Schem, C. Sotiriou, S. Loi, M. Untch, P. Conte, R. Bernards, M. Piccart, G. von Minckwitz & J. Baselga

*Ann Oncol* 2016; 27: 1519–1525 (doi: 10.1093/annonc/mdw197)

In the original article, the following funding information was omitted: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. This has now been added.